ADAM9 and lung cancer: By epigenetic modification, EZH2 benefits cancer cell survival, induces epithelial mesenchymal transition, and confers drug resistance.[92] Hsa_circ_0020123 is also a sponge for miR-488-3p, while miR-488-3p inhibits ADAM9 translation.[93] Overexpression of ADAM9 stimulates expression of vascular endothelial growth factor A, increases angiogenesis, promotes vascular remodeling, and correlates with metastasis and poor prognosis in lung cancer.[94,95]